Press release content from Business Wire. The AP news staff was not involved in its creation.
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration
February 25, 2021 GMT
BEIJING & CAMBRIDGE, Mass. (BUSINESS WIRE) Feb 25, 2021
CANbridge Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing drug candidates in China and North Asia, and Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, have agreed to terminate their 2018 license agreement, in which Puma granted CANbridge exclusive rights to develop and commercialize NERLYNX® (neratinib) in Greater China, and to settle their arbitration related to the license agreement.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Global $71.43 Billion Telepharmacy Market to 2027 - ResearchAndMarkets.com
February 25, 2021 GMT
DUBLIN (BUSINESS WIRE) Feb 25, 2021
ADVERTISEMENT
Telepharmacy refers to the process of delivering the pharmaceutical care through telecommunications to the patients across various locations where getting consultation from any healthcare professional is next to impossible. Telepharmacy is a subset of telemedicine which is a wider term used by the healthcare experts.
Certain services involved in telepharmacy includes patient counselling, drug therapy monitoring, refill authorization and prior authorization needed for the prescription drugs. Other telepharmacy services comprises of monitoring the formulary compliance through the deployment of videoconferencing or teleconferencing.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Fluor Reports Fourth Quarter and Full Year 2020 Results
February 26, 2021 GMT
IRVING, Texas (BUSINESS WIRE) Feb 26, 2021
Fluor Corporation (NYSE: FLR) today announced financial results for its year ended December 31, 2020. Results for 2020 were a net loss from continuing operations attributable to Fluor of $294 million, or $2.09 per diluted share, compared to a net loss from continuing operations attributable to Fluor of $1.5 billion, or $10.89 per diluted share in 2019. Consolidated segment profit for the year was $317 million compared to a loss of $186 million in 2019. Consolidated continuing operations for the year included non-cash impairments and charges of approximately $358 million to reflect the impact of weak commodity prices and COVID-19. Operating cash flow in 2020 was $186 million compared to $219 million in 2019.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent .
SpringWorks Therapeutics, Inc.February 25, 2021 GMT
- Reported Interim Data from Phase 2b ReNeu Trial of Mirdametinib in NF1-PN Demonstrating Encouraging Clinical Activity and Tolerability in the First 20 Adult Patients Enrolled - -
- Continued to Strengthen Nirogacestat Patent Portfolio -
- Multiple Data Readouts Expected in 2021 Across
Pipeline, Including Topline Data from Phase 3 DeFi Trial in Desmoid Tumors and Initial Nirogacestat BCMA Combination Data -
ADVERTISEMENT
- Ended 2020 with $561.8 Million in Cash, Cash Equivalents and Marketable Securities -